Most Read News


How much did listed pharmaceutical companies spend on SG&A expenses?

This year, the increase of collective selling, general & administrative(SG&A) expenses by the 3rd quarter of the year on average was 20 times higher in the KOSDAQ market than the one in the KOSPI. When it comes to the...

Pharmaceutical companies’ concerns over ‘Financial Gain & Expenditure Report’ even before it starts

While being active in preparing for the ‘Financial Gain & Expenditure Report’ which will be implemented from 1 January 2018, pharmaceutical companies have encountered a new concern. When the report became obligated, ...

Pharmaceutical companies’ ‘two-faced’ viewpoint towards ISO37001

‘Will they move?” The industry has paid attention to whether pharmaceutical companies will be active on the ISO 37001 certification process the Pharmaceutical and Bio-Pharma Manufacturers Association adopted as part ...

Chairman Sun-Hye Cho, “I’ll lead coexistence with the idea of ‘strong association’”

Geo-Young Chairman Sun-Hye Cho formalized to run for the 35th Korea Pharmaceutical Distribution Association Presidential Election. At a meeting with Yakup Shinmoon on the 21st, Chairman Sun-Hye Cho said “The pharmace...

6 CEOs in pharma industry received more than KRW 500 million wages for the past 9 months

Wages for 6 CEOs in the pharmaceutical industry, including Boryung Pharm Chairman Eun-Sun Kim, reportedly exceeded KRW 500 million for the past 9 months.  Yakup Shinmoon(www.yakup.com) analyzed 2017 3rd quarter repor...

Non-small cell lung cancer treatment ‘Tagrisso’ applied for health insurance benefits from 5 December

The health insurance benefits of ‘Tagrisso,’ a non-small cell lung cancer treatment completed with the drug price negotiation, was decided registration and will be applied from 5 December. Compensation plans for the ...

Green Cross wins largest blood product tender ever

Green Cross has drawn the largest exports of blood product ever. Green Cross(CEO Eun-Cheol Huh) announced on the 22nd that the company obtained an order of IV-Globulin SN(IVIG-SN) worth of USD 42.9 million(KRW 47 bil...

Which pharmaceutical companies spent the most in R&D?

KOSPI pharmaceutical companies increased collective R&D expenses by this 3rd quarter year-on-year, but KOSDAQ pharmaceutical companies had a decrease. When it comes to the collective 3rd quarter’s R&D expense/sales ra...

Series of medicines running out of stock or suspended manufacturing due to problems in ingredient supply

With the unstable ingredient supply and manufacturing delays, there have been an endless number of medicines running temporary out-of-stock or suspended manufacturing. According to the industry concerned, Sanofi-Aven...

Materials for medicine reassessment get stricter

In the future, when applying for reassessment for a novel drug, a pharmaceutical company must turn in reference data, such as sales and approval records. On 21 November, the Ministry of Food and Drug Safety(MFDS) off...

Rapid decrease of bioequivalently-recognized medicines shows pharmaceutical companies’ hesitation over generic development

Medicines which have been newly recognized in bioequivalence test this year were 481 products, the number was decreased by almost a half compared to the last year’s same time of period. According to the Ministry of F...

Most common adverse drug reaction with both ETC and OTC was gastrointestinal disorder

The most common adverse drug reaction with ETC and OTC drugs was gastrointestinal disorder. Na-Young Lee, Jung-Min Lee and Mo-Sae Lee(Korean Pharmaceutical Association Local Drug Safety Center) announced the ‘Compari...

“Gleevec generics have no bioequivalent problem, and prescribing is a matter of the medical field”

The Ministry of Food and Drug Safety(MFDS) made straight that there was no problem for the Gleevec generics’ bioequivalence test in safety and efficacy, but prescribing generics over Gleevec is not a matter of issue t...

Vemlidy and Besivo enters Severance Hospital at the same time

‘Vemlidy,’ a Gilead Sciences/Yuhan Corporation’s chronic hepatitis B treatment whose health insurance benefits have been applied from 1 November, and Ildong Pharmaceutical’s ‘Besivo’ entered in Severance Hospital. Se...

Kwang Dong signs a Korean exclusive license agreement of female sexual desire disorder treatment

Kwang Dong Pharmaceutical(CEO Sung-Won Choi) announced on the 22nd that it signed a Korean exclusive license agreement of ‘bremelanotide,’ a substance candidate of novel drug developed by U.S. Palatin Technologies for...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.